HomeInsightsStock Comparison

Ipca Laboratories Ltd vs Neuland Laboratories Ltd Stock Comparison

Ipca Laboratories Ltd vs Neuland Laboratories Ltd Stock Comparison

Last Updated on: May 01, 2025

Key Highlights

  • The Latest Trading Price of Ipca Laboratories Ltd is ₹ 1396 as of 30 Apr 15:30.
  • The P/E Ratio of Ipca Laboratories Ltd changed from 28.9 on March 2020 to 57.4 on March 2024 . This represents a CAGR of 14.71% over 5 yearsThe P/E Ratio of Neuland Laboratories Ltd changed from 22.5 on March 2020 to 27 on March 2024 . This represents a CAGR of 3.71% over 5 years.
  • The Market Cap of Ipca Laboratories Ltd changed from ₹ 17538 crore on March 2020 to ₹ 31414 crore on March 2024 . This represents a CAGR of 12.36% over 5 yearsThe Market Cap of Neuland Laboratories Ltd changed from ₹ 363.66 crore on March 2020 to ₹ 8058 crore on March 2024 . This represents a CAGR of 85.83% over 5 years.
  • The revenue of Ipca Laboratories Ltd for the Dec '24 is ₹ 2265 crore as compare to the Sep '24 revenue of ₹ 2381 crore. This represent the decline of -4.86% The revenue of Neuland Laboratories Ltd for the Dec '24 is ₹ 457.72 crore as compare to the Sep '24 revenue of ₹ 315.18 crore. This represent the growth of 45.22%.
  • The ebitda of Ipca Laboratories Ltd for the Dec '24 is ₹ 483.19 crore as compare to the Sep '24 ebitda of ₹ 467.74 crore. This represent the growth of 3.3% The ebitda of Neuland Laboratories Ltd for the Dec '24 is ₹ 146.28 crore as compare to the Sep '24 ebitda of ₹ 66.56 crore. This represent the growth of 119.77%.
  • The net profit of Ipca Laboratories Ltd changed from ₹ 166.21 crore to ₹ 277.33 crore over 7 quarters. This represents a CAGR of 33.98% The net profit of Neuland Laboratories Ltd changed from ₹ 61.88 crore to ₹ 101.59 crore over 7 quarters. This represents a CAGR of 32.75% .
  • The Dividend Payout of Ipca Laboratories Ltd changed from 9.68 % on March 2020 to 19.13 % on March 2024 . This represents a CAGR of 14.60% over 5 yearsThe Dividend Payout of Neuland Laboratories Ltd changed from 16.25 % on March 2020 to 6.03 % on March 2024 . This represents a CAGR of -17.99% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Ipca Laboratories Ltd

  • Ipca Laboratories Limited (IPCA) was incorporated on 19th October, 1949 under the name of 'The Indian Pharmaceutical Combine Association Limited.' Ipca is a fully integrated, pharmaceutical company manufacturing and marketing over 350 formulations and 80 API's covering various therapeutic segments.
  • The products of the Company are now sold in over 100 countries across the globe.
  • The Company has 18 manufacturing units in India manufacturing API's and formulations for the world market. Ipca's APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries.

About Neuland Laboratories Ltd

  • Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao.
  • The Company is engaged in manufacturing and selling of bulk drugs such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin.
  • Neuland Drugs & Pharmaceuticals Pvt.
  • Ltd., a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992.
  • NLL manufactures bulk drugs. The Company came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix.

Ipca Laboratories Ltd News Hub

News

Ipca Laboratories appoints President - Human Resources

Ipca Laboratories has appointed Saidutta Nanda as President - Human Resources of the compa...

Read more

03 Mar 2025 16:06

News

Ipca Laboratories Ltd down for fifth straight session

Ipca Laboratories Ltd is down for a fifth straight session today. The stock is quoting at ...

Read more

28 Feb 2025 13:35

News

Ipca Labs spurts after Q3 PAT soars to Rs 267 cr

Revenue from operations jumped 10.34% YoY to Rs 1,662.68 crore in the quarter ended 31st D...

Read more

13 Feb 2025 15:03

News

Ipca Laboratories to announce Quarterly Result

Ipca Laboratories will hold a meeting of the Board of Directors of the Company on 13 Febru...

Read more

27 Jan 2025 14:16

News

Ipca Laboratories Ltd spurts 0.49%, rises for fifth straight session

Ipca Laboratories Ltd gained for a fifth straight session today. The stock is quoting at R...

Read more

01 Jan 2025 13:00

News

Ipca Laboratories Ltd soars 1.49%, rises for third straight session

Ipca Laboratories Ltd rose for a third straight session today. The stock is quoting at Rs ...

Read more

30 Dec 2024 13:05

Neuland Laboratories Ltd News Hub

News

Neuland Laboratories to announce Quarterly Result

Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 15 Ma...

Read more

25 Apr 2025 10:43

News

Neuland Laboratories Ltd Spurts 2.02%

Neuland Laboratories Ltd gained 2.02% today to trade at Rs 13000. The BSE Healthcare index...

Read more

17 Apr 2025 09:30

News

Neuland Laboratories appoints Head - Manufacturing

Neuland Laboratories announced that Parag Deshmukh has been appointed as Head - Manufactur...

Read more

10 Mar 2025 15:29

News

Neuland Laboratories receives affirmation in credit ratings

Neuland Laboratories announced that India Ratings and Research has affirmed the credit rat...

Read more

10 Mar 2025 15:26

News

Neuland Laboratories Ltd leads gainers in 'A' group

Vesuvius India Ltd, Pfizer Ltd, Data Patterns (India) Ltd and Orchid Pharma Ltd are among ...

Read more

24 Feb 2025 12:00

News

Neuland Laboratories Ltd Falls 3.78%

Neuland Laboratories Ltd lost 3.78% today to trade at Rs 13142.7. The BSE Healthcare index...

Read more

12 Feb 2025 09:30

SWOT Analysis Of Ipca Laboratories Ltd

Strength

2

S

Weakness

4

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Neuland Laboratories Ltd

Strength

5

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Ipca Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Neuland Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Ipca Laboratories Ltd and Neuland Laboratories Ltd

Which company has a larger market capitalization, Ipca Laboratories Ltd or Neuland Laboratories Ltd?

Market cap of Ipca Laboratories Ltd is 35,431 Cr while Market cap of Neuland Laboratories Ltd is 15,443 Cr

What are the key factors driving the stock performance of Ipca Laboratories Ltd and Neuland Laboratories Ltd?

The stock performance of Ipca Laboratories Ltd and Neuland Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ipca Laboratories Ltd and Neuland Laboratories Ltd?

As of May 1, 2025, the Ipca Laboratories Ltd stock price is INR ₹1396.55. On the other hand, Neuland Laboratories Ltd stock price is INR ₹12036.9.

How do dividend payouts of Ipca Laboratories Ltd and Neuland Laboratories Ltd compare?

To compare the dividend payouts of Ipca Laboratories Ltd and Neuland Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions